Nektar Therapeutics
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| 0UNL.L | 068270.KS | NKTX | BIIB | ARTV | AMGN | |
|---|---|---|---|---|---|---|
| Market cap | — | 45.19T | 127.85M | 34.79B | 286.98M | 231.84B |
| P/E (TTM) | — | — | — | 41.8 | — | 26.6 |
| Forward P/E | — | — | -1.0 | 14.2 | -2.3 | 17.5 |
| Price/book | 1.4 | — | 0.5 | 1.8 | 0.8 | 19.8 |
| Dividend yield | — | 0.37% | — | — | — | 2.33% |
| 1-year change | — | +15.02% | −26.23% | +58.66% | +19.14% | +42.58% |
| Today | −5.00% | +2.16% | −0.83% | +1.19% | +0.34% | −0.84% |
The closest companies by business. Prices may be delayed up to 20 min.
Latest news
All 0UNL.L news ›Nektar Therapeutics (NASDAQ:NKTR) Now Covered by Analysts at Leerink Partners
Posted by Sarita Garza on Oct 13th, 2026 Leerink Partners assumed coverage on shares of Nektar Therapeutics (NASDAQ:NKTR – Free Report) in a research report released on Monday morning, Marketbeat Ratings reports. The brokerage issued an…
BTIG reiterates Buy rating on Nektar Therapeutics, $178 price target
BTIG reiterated their Buy rating on Nektar Therapeutics's stock with a price target of $178.00. The price target implies an upside of 336.3% from the Oct 8 close of $40.80. Positive Initial Legal Outcomes: The favorable outcome of the…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
themarketsdaily.com3
-
tradingview.com3
-
seekingalpha.com2
-
gurufocus.com1
-
kalkinemedia.com1
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 11 articles, not a forecast.